Josephine Warren1, Roxana Mehran2, Usman Baber1, Ke Xu3, Daniele Giacoppo1, Bernard J Gersh4, Giulio Guagliumi5, Bernhard Witzenbichler6, E Magnus Ohman7, Stuart J Pocock8, Gregg W Stone9. 1. Icahn School of Medicine at Mount Sinai, New York, NY. 2. Icahn School of Medicine at Mount Sinai, New York, NY; Cardiovascular Research Foundation, New York, NY. Electronic address: roxana.mehran@mountsinai.org. 3. Cardiovascular Research Foundation, New York, NY. 4. Mayo Clinic College of Medicine, Rochester, MN. 5. Ospedale Papa Giovanni XXIII, Bergamo, Italy. 6. Helios Amper-Klinikum, Dachau, Germany. 7. Duke University Medical Center, Durham, NC. 8. Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London, United Kingdom. 9. Cardiovascular Research Foundation, New York, NY; NewYork-Presbyterian Hospital/Columbia University Medical Center, New York, NY.
Abstract
BACKGROUND:Acute kidney injury (AKI) is a well-recognized predictor of morbidity and mortality after percutaneous coronary intervention. However, the impact of AKI on the outcome of patients with acute coronary syndromes (ACS) in relation to coronary artery bypass grafting (CABG) has not been established. METHODS: Of the 17,421 patients who presented with non-ST-segment elevation ACS or ST-segment elevation myocardial infarction enrolled in the ACUITY and HORIZONS-AMI trials, 1,406 (8.0%) underwentCABG as principal treatment after coronary angiography. End points were measured at 1 month and 1 year and included death, myocardial infarction, and ischemia-driven target vessel revascularization. Acute kidney injury was defined as a rise in creatinine of ≥ 0.5 mg/dL, or > 25%, from baseline at initial angiography. RESULTS:Acute kidney injury occurred during hospital admission in 449 (31.9%) of the 1,406 patients treated with CABG. One-month and 1-year mortality was 6.7% vs 2.2% (P < .0001) and 10.4% vs 4.3% (P < .0001) for patients with vs without AKI, respectively. Analogously, the 1-month and 1-year incidence of composite major adverse cardiac events (MACEs; death, MI, or target vessel revascularization) was 17.6% vs 12.4% (P = .003) and 22.0% vs 15.3% (P = .002) for patients with vs without AKI, respectively. After adjustment for age, sex, race, diabetes, hypertension, and baseline creatinine clearance, AKI was an independent predictor of mortality (overall and cardiac-related) and MACE at both 1 month and 1 year in patients treated with CABG. CONCLUSIONS:Acute kidney injury occurred in approximately 1 of every 3 patients with ACS treated with CABG and is a powerful independent predictor of death and MACE. These data highlight the need for AKI prevention strategies in patients undergoing CABG.
RCT Entities:
BACKGROUND:Acute kidney injury (AKI) is a well-recognized predictor of morbidity and mortality after percutaneous coronary intervention. However, the impact of AKI on the outcome of patients with acute coronary syndromes (ACS) in relation to coronary artery bypass grafting (CABG) has not been established. METHODS: Of the 17,421 patients who presented with non-ST-segment elevation ACS or ST-segment elevation myocardial infarction enrolled in the ACUITY and HORIZONS-AMI trials, 1,406 (8.0%) underwent CABG as principal treatment after coronary angiography. End points were measured at 1 month and 1 year and included death, myocardial infarction, and ischemia-driven target vessel revascularization. Acute kidney injury was defined as a rise in creatinine of ≥ 0.5 mg/dL, or > 25%, from baseline at initial angiography. RESULTS:Acute kidney injury occurred during hospital admission in 449 (31.9%) of the 1,406 patients treated with CABG. One-month and 1-year mortality was 6.7% vs 2.2% (P < .0001) and 10.4% vs 4.3% (P < .0001) for patients with vs without AKI, respectively. Analogously, the 1-month and 1-year incidence of composite major adverse cardiac events (MACEs; death, MI, or target vessel revascularization) was 17.6% vs 12.4% (P = .003) and 22.0% vs 15.3% (P = .002) for patients with vs without AKI, respectively. After adjustment for age, sex, race, diabetes, hypertension, and baseline creatinine clearance, AKI was an independent predictor of mortality (overall and cardiac-related) and MACE at both 1 month and 1 year in patients treated with CABG. CONCLUSIONS:Acute kidney injury occurred in approximately 1 of every 3 patients with ACS treated with CABG and is a powerful independent predictor of death and MACE. These data highlight the need for AKI prevention strategies in patients undergoing CABG.
Authors: Yaron Arbel; Valentin Fuster; Usman Baber; Taye H Hamza; F S Siami; Michael E Farkouh Journal: Int J Cardiol Date: 2019-06-13 Impact factor: 4.164
Authors: Alan S Go; Chi-Yuan Hsu; Jingrong Yang; Thida C Tan; Sijie Zheng; Juan D Ordonez; Kathleen D Liu Journal: Clin J Am Soc Nephrol Date: 2018-05-17 Impact factor: 8.237
Authors: Mitra K Nadim; Lui G Forni; Azra Bihorac; Charles Hobson; Jay L Koyner; Andrew Shaw; George J Arnaoutakis; Xiaoqiang Ding; Daniel T Engelman; Hrvoje Gasparovic; Vladimir Gasparovic; Charles A Herzog; Kianoush Kashani; Nevin Katz; Kathleen D Liu; Ravindra L Mehta; Marlies Ostermann; Neesh Pannu; Peter Pickkers; Susanna Price; Zaccaria Ricci; Jeffrey B Rich; Lokeswara R Sajja; Fred A Weaver; Alexander Zarbock; Claudio Ronco; John A Kellum Journal: J Am Heart Assoc Date: 2018-06-01 Impact factor: 5.501
Authors: William D Carlson; Peter C Keck; Dattatreyamurty Bosukonda; Frederic Roy Carlson Journal: Front Pharmacol Date: 2022-07-08 Impact factor: 5.988
Authors: Zijin Chen; Charles E McCulloch; Neil R Powe; Michael Heung; Rajiv Saran; Meda E Pavkov; Nilka Rios Burrows; Raymond K Hsu; Chi-Yuan Hsu Journal: BMC Nephrol Date: 2020-08-10 Impact factor: 2.388